Patent 11066656

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (3)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2020-07-01 · Assignment

    CONNOR, ROBERT JAMES, WEI, GE, ZHAO, QipingHALOZYME THERAPEUTICS, INC.

    internal reorg

  2. 2020-07-01 · Assignment

    SHEPARD, H. MICHAELHALOZYME, INC.

    internal reorg

  3. 2020-07-01 · Assignment

    HALOZYME THERAPEUTICS, INC.HALOZYME, INC.

    internal reorg

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Ge Wei (likely Halozyme Inc.)
  • H. Michael Shepard (likely Halozyme Inc.)
  • Qiping Zhao (likely Halozyme Inc.)
  • Robert James Connor (likely Halozyme Inc.)

The inventors assigned their rights to Halozyme entities shortly after the patent application was filed, which is a standard practice for employee inventions. No unusual patterns suggest inventors departing the original assignee around the time of filing or assignment.

Original assignee

The original assignee named on the issued patent is Halozyme Inc. Halozyme Therapeutics, Inc. (and by extension Halozyme Inc.) is a publicly traded biopharmaceutical company (NASDAQ: HALO) that develops and commercializes drug delivery solutions, primarily its ENHANZE® technology, which utilizes a recombinant human hyaluronidase enzyme (rHuPH20) to enable subcutaneous administration of injectable biologics. The company ships products embodying the claims, such as Hylenex recombinant and XYOSTED®, and licenses its technology to major pharmaceutical companies. Halozyme Therapeutics, Inc. is currently operating and has a market capitalization of approximately $8.18 billion as of March 31, 2026.

Assignment timeline

Note: Reel/Frame, Recording Date, and Correspondent information are not available from the Google Patents Legal Events timeline, which serves as the source for these events.

  • 2020-07-01 (executed) / recorded 2020-07-01 (implied)

    • Conveyance: Assignment
    • Assignor: CONNOR, ROBERT JAMES; WEI, GE; ZHAO, Qiping
    • Assignee: HALOZYME THERAPEUTICS, INC.
    • Correspondent: Not available from source.
    • Context: Internal reorg (inventor assignment to employing entity)

  • 2020-07-01 (executed) / recorded 2020-07-01 (implied)

    • Conveyance: Assignment
    • Assignor: SHEPARD, H. MICHAEL
    • Assignee: HALOZYME, INC.
    • Correspondent: Not available from source.
    • Context: Internal reorg (inventor assignment to employing entity)

  • 2020-07-01 (executed) / recorded 2020-07-01 (implied)

    • Conveyance: Assignment
    • Assignor: HALOZYME THERAPEUTICS, INC.
    • Assignee: HALOZYME, INC.
    • Correspondent: Not available from source.
    • Context: Internal reorg (transfer between related corporate entities)

Timeline diagram

timeline
    title Ownership of US 11066656
    2020 : Application filed by Halozyme Inc
         : Inventors Connor, Wei, Zhao assign to Halozyme Therapeutics Inc
         : Inventor Shepard assigns to Halozyme Inc
         : Halozyme Therapeutics assigns to Halozyme Inc
    2021 : Patent issued to Halozyme Inc

NPE / troll-pattern signals

  1. Shell-entity transfer — Not present. The transfers are between Halozyme Therapeutics, Inc. and Halozyme, Inc., which are identified as active operating companies.
  2. Known asserter in the chain — Not present. Halozyme Inc. and Halozyme Therapeutics Inc. are well-known operating biopharmaceutical companies.
  3. Repeat correspondent across the chain — Unclear. Correspondent information is not available from the Google Patents legal events timeline, so this signal cannot be assessed.
  4. Cascading transfers — Not present. Although multiple assignments occurred on the same day (2020-07-01), they represent a coordinated set of internal assignments from inventors and a related corporate entity (Halozyme Therapeutics, Inc.) to consolidate ownership under Halozyme, Inc. This is distinct from rapid transfers between unrelated shell entities.
  5. Pre-litigation transfer — Not present. The assignments occurred on 2020-07-01. While Google Patents indicates a "US case filed in New Jersey District Court" with a case number suggesting a 2025 filing (2:25-cv-03179), this is more than 6 months after the recorded assignments.
  6. Bankruptcy fire-sale — Not present. Halozyme Therapeutics, Inc. is an actively operating public company.
  7. Privateering — Not present. Halozyme Therapeutics, Inc. is an operating company that retains ownership of the patent.
  8. Defensive aggregator (anti-NPE) — Not present. The patent remains under the ownership of an operating company, not a defensive aggregator.

Verdict

Operating-company assertion. The assignment records from 2020-07-01 demonstrate a clear chain of title from the individual inventors to Halozyme Therapeutics, Inc., and then consolidating within Halozyme, Inc. Halozyme Inc. is a recognized operating biopharmaceutical company that produces and licenses products related to the patented technology, showing no indications of being a shell entity or a known NPE.

Verification: https://assignmentcenter.uspto.gov/

Generated 5/29/2026, 5:55:16 PM